Linked Life Data

18477967

Source:http://linkedlifedata.com/resource/pubmed/id/18477967

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2008-5-14
pubmed:abstractText
Recent evidence suggests that there is a link between increased colonic inflammation and risk of colorectal cancer, stressing the importance of preventing relapse. The risk of relapse is associated with several factors, of which the foremost is patient nonadherence to prescribed medical therapy. Nonadherence may be affected by such factors as complicated dosing regimens, forgetfulness, male sex, and treatment delivery methods. Mesalamine is the standard, first-line therapy and the treatment of choice for inducing and maintaining clinical and endoscopic remission of inflammation in patients with mild-to-moderate ulcerative colitis. Novel formulations of mesalamine and newly devised, high-dose regimens offer additional therapeutic options and may lead to improved treatment adherence, longer-lasting periods of remission, and enhanced patient well-being.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1533-001X
pubmed:author
pubmed:issnType
Print
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
21-30; quiz 31-2
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Maximizing patient adherence and clinical outcomes with mesalamine in mildly-to-moderately active ulcerative colitis.
pubmed:affiliation
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
pubmed:publicationType
Journal Article, Review